Nebivolol

Structure: Third-generation beta blocker supplied as a racemic mixture. The d-isomer provides highly selective beta-1 adrenergic blockade (the rate-slowing effect); the l-isomer stimulates endothelial nitric oxide release via beta-3 agonism, producing genuine vasodilation. That nitric oxide component is what separates nebivolol from atenolol, metoprolol, and propranolol.

Dosage:

• Starting: 2.5-5mg once daily
• Titration: increase at 2-week intervals; usual effective range 5-10mg/day, maximum 40mg/day
• On-cycle blood pressure control: 2.5-5mg/day is usually enough, particularly alongside an ARB. Higher doses noticeably cap training heart rate.

Administration:

• Oral, once daily, with or without food, at a consistent time
• Full antihypertensive effect takes about 2 weeks per dose step
• Never stop abruptly after chronic use. Beta receptor upregulation causes rebound tachycardia, hypertension, and angina. Taper over 1-2 weeks.

Key Notes:

• The beta-1 selectivity plus nitric oxide vasodilation means less of the classic beta blocker baggage: less bronchospasm, less exercise fatigue, and less erectile dysfunction than older agents.
• The metabolic profile is the reason it gets picked for enhanced athletes. Propranolol and atenolol raise triglycerides, lower HDL, and worsen insulin sensitivity. Nebivolol is neutral to mildly favourable on both counts in trials. On a cycle that has already flattened HDL, adding a drug that lowers it further is a bad trade.
• Heart rate blunting is the main complaint from lifters. Expect resting heart rate to fall 8-15 bpm and peak heart rate to be capped. Cardio feels harder at the same output and heart-rate-based training zones stop being meaningful. Switch to RPE or pace.
• It is not first-line for the hypertension of a heavy cycle. AAS-driven hypertension is largely volume expansion and RAAS activation, which an ARB such as Telmisartan addresses more directly. Nebivolol is the add-on when resting heart rate is also elevated, or when an ARB alone is not enough.
• Combines reasonably with a low-dose PDE5 inhibitor; watch for additive hypotension when stacking three antihypertensive mechanisms.
• Directly opposes Clenbuterol. Running both makes no pharmacological sense, though beta blockers are the standard treatment for clenbuterol overdose tachycardia.
• Masks the adrenergic warning signs of hypoglycaemia (tremor, palpitations). Genuinely dangerous if you use Insulin, since sweating may be the only warning left.
• Additive bradycardia with verapamil and diltiazem. Avoid the combination without supervision.
• Beta blockers are prohibited in certain sports (archery, shooting, some others) under the WADA list. Check your federation before an event.
• Not hormonal, not suppressive, and no interaction with AAS, peptides, or GH on the endocrine side.

Bloodwork Monitoring:

• Home blood pressure and resting heart rate are the primary monitoring, not bloods. Log morning and evening readings for a week before starting and again 2-4 weeks after, seated and rested.
• Lipids at baseline and 8-12 weeks: Total Cholesterol, HDL, LDL, Triglycerides. Nebivolol should leave these alone. If they deteriorate, the cycle is the cause, not the beta blocker.
• Fasting Glucose and HbA1c: worth including if you are also running GH, MK-677, or insulin. Metabolic neutrality is relative, not absolute.
• Potassium, Creatinine, and eGFR if combined with an ARB or ACE inhibitor.
• Haematocrit remains an AAS problem that a beta blocker does not touch. Treating blood pressure does not treat erythrocytosis, and high haematocrit is its own cardiovascular risk.